Industry News

Ligand Pharmaceuticals Incorporated announces the licensing of rights to four programs to Seelos Therapeutics, Inc., a newly formed biopharmaceutical company focused on central nervous system, respiratory and other disorders. The licensed therapeutic programs include Ligand's aplindore program for the treatment of various CNS disorders, a CRTH2 antagonist program for the treatment of respiratory disorders, a Captisol-enabled™ acetaminophen program for..."/>
Ligand Licenses Four Programs to Seelos Therapeutics
Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced it will present at the Leerink Partners Immuno-Oncology Roundtable on Thursday, September 29, 2016 at 8:30 a.m. Eastern Time in New York, NY. The presentation will be webcast live and..."/>
Calithera Biosciences to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Roundtable
pSivida Corp., a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that Nancy Lurker, the Company’ s newly-appointed President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, September 27, 2016 at 1:30 pm. ET. The conference will be held at the Sofitel Hotel in New York City.. The presentation will be webcast at..."/>
PSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference
Kiwa Bio-Tech Products Group Corporation is pleased to announce that Japanese Chuon Co., LTD visited Kiwa Bio-Tech Co., LTD in Beijing recently to discuss the role of biotechnology in agriculture and advanced methods of controlling“ desert”- ification. Desertification is the process by which fertile land becomes desert, typically as a result of drought, deforestation, or inappropriate agriculture. “In recent years we have witnessed a robust..."/>
Kiwa Announces strategic relationship with Chuon Co., LTD, of Japan
Pacific Biosciences of California, Inc.,, and Dovetail Genomics™ LLC today announced that Dovetail has added PacBio ® SMRT ® sequencing and de novo assembly options to its menu of genome assembly services. The companies also announced their signing of a co-marketing agreement under which the new service offerings will be jointly promoted. "We are impressed by Dovetail's continued commitment to deliver the most..."/>
Dovetail Genomics Adds PacBio SMRT Sequencing and Assembly to Its Services Menu
Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced the completion of its previously announced private placement of an aggregate of approximately 22,500 shares of the Company's Series A Preferred Stock and five-year warrants to purchase an aggregate of approximately 32,142,857 shares of the Company's common stock for gross..."/>
Roka Bioscience, Inc. Completes Private Placement of Preferred Stock and Warrants
Compass Diversified Holdings, an owner of leading middle market businesses, announced that on September 21, 2016 it entered into a definitive agreement and consummated the sale of its majority owned subsidiary, Anodyne Medical Device, Inc., also doing business and known as Tridien Medical, to Hill-Rom, Inc.. CODI does not expect to record a significant gain or loss as a result of the sale. The proceeds will be used to pay down outstanding debt..."/>
Compass Diversified Holdings Announces Sale of Tridien Medical
Response Biomedical Corp.– Further to TSX Bulletin 2016-0859 dated August 26, 2016, TSX has decided to extend its review of the eligibility of the common shares of the Company for continued listing for a period of 60 days. TMX Group's key subsidiaries operate cash and derivative markets and clearinghouses for multiple asset classes including equities, fixed income and energy. Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha..."/>
TSX Delisting Review - Response Biomedical Corp. (Symbol: RBM)
ViewRay, Inc., makers of the world's first and only clinical MRI-guided radiation therapy system, announced today that the company's MRIdian System and MRIdian Linac technology will be featured at the Annual Meeting of the American Society for Radiation Oncology, to be held September 25-28, 2016 in Boston. MRI-guided radiation therapy continues to be a topic of significant interest, as reflected by the 18 MRIdian clinical presentations..."/>
ViewRay MRIdian Clinical Experience to be highlighted by Five Leading Centers at Largest Radiation Oncology Meeting
Imprimis Pharmaceuticals, Inc., a pharmaceutical company dedicated to making drugs affordable through its Branded Compounding™ business model, published a 75- page well-referenced drug pricing monograph describing specific proposals that will drive competition, transparency and patient access by lowering drug costs for Americans. Imprimis is known for its Imprimis Cares ® program and a 99 cent alternative to the $750 per pill..."/>
Following Congressional Hearing Investigating Mylan and Epi-Pen, Imprimis Pharmaceuticals Founder and CEO Publishes Drug Pricing Monograph
Eleven Biotherapeutics announced on Wednesday that it awarded inducement equity award to Stephen Hurly as, Arthur P. DeCillis, MD, Glen MacDonald, PhD and Gregory P. Adams, PhD as in connection with their new employment outside its 2014 stock incentive plan. In connection with the new employments, the company awarded Hurley, Dr DeCillis, Dr MacDonald and Dr Adams with a stock option to purchase 350,000, 100,000, 100,000 and 100,000 shares of its common stock,..."/>
Eleven Biotherapeutics grants stock options to four new executives under NASDAQ Listing Rule 5635(c)(4)
Syros Pharmaceuticals announced today that the first patient has been dosed in the Phase 2 clinical trial of its lead drug candidate, SY-1425, a first-in-class selective retinoic acid receptor alpha agonist, in genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome identified using a novel biomarker discovered by its gene control platform. “This is an important milestone for..."/>
Syros Announces First Patient Enrolled in Phase 2 Clinical Trial of SY-1425 in Genomically Defined Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
VistaGen Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system, today provided a business outlook including the clinical status of its flagship CNS product candidate, AV-101, currently in Phase 2 development for the treatment of major depressive disorder,..."/>
VistaGen Therapeutics Provides Business Outlook and Sets Corporate Milestones
Aurinia Pharmaceuticals Inc.,, a clinical stage biopharmaceutical company focused on the global immunology market, today announced that its Chief Executive Officer, Charles Rowland, will participate in a Fireside Chat at the Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology on September 28, 2016 at 11:05am ET in New York. To access the live webcast, please visit the investor section of the Aurinia website. A replay will also be..."/>
Aurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28, 2016
Enumeral Biomedical Holdings, Inc., a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that Wael Fayad has been appointed Chairman, President, and Chief Executive Officer of the Company, effective as of September 21, 2016.. Fayad brings to Enumeral more than two decades of senior executive and business development experience..."/>
Enumeral Appoints Wael Fayad as Chairman, President and Chief Executive Officer
AntriaBio, Inc., a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it is forming a new wholly owned subsidiary in Seoul, South Korea to focus on research and development as well as potential manufacturing opportunities. AntriaBio intends to simultaneously begin raising capital primarily from Korean institutional investors with a goal of closing the financing prior to the end of 2016. The..."/>
AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer and other diseases, announced today that Christopher Kiritsy has joined the Company's Board of Directors, bringing the total number of directors to seven. Kiritsy is a co-founder of Arisaph Pharmaceuticals, Inc. and has served as Arisaph's President and Chief Executive Officer..."/>
Pieris Pharmaceuticals Appoints Christopher Kiritsy to Its Board of Directors
Teladoc, Inc., the nation’ s leading provider of telehealth services, today announced that David Shedlarz, former vice chairman, executive vice president and chief financial officer of Pfizer Inc., has been appointed to its board of directors. This appointment comes on the heels of last quarter's board addition, Helen Darling, with both appointments responding to the need to support the rapidly expanding foothold Teladoc has secured in the evolving..."/>
Teladoc Appoints Former Pfizer Vice Chairman and CFO David Shedlarz to Board of Directors
Rockwell Medical, Inc., a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today provided an update on the commercial launch of Calcitriol, stating that stability data for completed finished product for commercial sale continues to remain within specification."/>
Rockwell Medical Preparing for Calcitriol Commercial Launch
Aduro Biotech, Inc. today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the LEERINK Partners Roundtable Series: Rare Disease& Immuno-Oncology in New York, NY on Thursday, September 29, 2016, at 8:00 am Eastern Time.. To access the live webcast and subsequent archived recording of this and the company’ s other presentations, please visit Aduro's website at www.aduro.com."/>
Aduro Biotech to Present at LEERINK Partners Roundtable Series
T2 Biosystems, Inc., a company developing innovative diagnostic products to improve patient health, today announced the purchase by Canon U.S.A., of approximately $40 million of the company’ s stock in a private placement. The shares were purchased at $6.56, the closing market price of Tuesday, September 20, 2016. With this investment, Canon owns 19.9 percent of T2 Biosystems and Canon’ s chief administrative officer and general counsel, Seymour..."/>
T2 Biosystems Announces $40 Million Equity Investment by Partner Canon U.S.A.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology693 Articles
Consumer Discretionary588 Articles
Financials455 Articles
Industrials385 Articles
Health Care382 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.